Category Archives: News & Events

In memoriam of Dr. Isabelle Tabah-Fisch

In memoriam of Dr. Isabelle Tabah-Fisch

Toulouse and Paris, August 31, 2020

GamaMabs is deeply saddened to learn the death of Isabelle Tabah-Fisch, its former Chief Medical Officer, on August 28.

Isabelle joined GamaMabs Pharma in November 2016 to bring us her remarkable expertise in Oncology and her high-level network which enabled her to design and implement our clinical trials, until her retirement in March 2020.

Despite the illness that affected her for two years, Isabelle displayed admirable professionalism, courage and energy.

Beyond her professional qualities, we will always remember Isabelle’s great vitality, her joie de vivre, her motivation for therapeutic progress and her ethical standards.

Our hearts go out to Isabelle’s family, especially her father and 3 children.

May Isabelle rest in peace.

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Pauline Estupina et al., Oncotarget February 2017

Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).

Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget

AMH_2017_Estupina_Oncotarget